<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01511549</url>
  </required_header>
  <id_info>
    <org_study_id>TDU11333</org_study_id>
    <secondary_id>U1111-1121-4499</secondary_id>
    <nct_id>NCT01511549</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics of SAR113945 in Japanese Patients With Knee Osteoarthritis</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Ascending Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SAR113945 (IKK Inhibitor) Following Intra-articular Administration in Japanese Patients With Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To assess the safety and tolerability of SAR113945 in Japanese patients with knee
      osteoarthritis after ascending single intra-articular doses

      Secondary Objective:

      To assess the pharmacokinetics of SAR113945 in Japanese patients with knee osteoarthritis
      after ascending single intra-articular doses
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following the single dose of study medication, the study period for each patient will be 168
      days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with safety assessments (adverse events, vital signs, 12 lead ECGs and laboratory tests)</measure>
    <time_frame>up to 24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Examination of skin/soft tissue of injected knee, and knee joint</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Examination of skin/soft tissue of injected knee: Any reaction is classified as erythema, edema, pain, hematoma and graded none, mild, moderate or severe.
Examination of knee joint of injected knee: Any reaction is classified as effusion/worsening of effusion, warmth and pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter (AUC)</measure>
    <time_frame>21 time points up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter (Cmax)</measure>
    <time_frame>21 time points up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter (tmax)</measure>
    <time_frame>21 time points up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter (t1/2)</measure>
    <time_frame>21 time points up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic parameter (WOMAC index)</measure>
    <time_frame>up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic parameter (biomarkers relating to osteoarthritis)</measure>
    <time_frame>up to 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAR113945 low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAR113945 medium dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAR113945 high dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Pharmaceutical form:injection
Route of administration: intra-articular</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAR113945</intervention_name>
    <description>Pharmaceutical form:injection
Route of administration: intra-articular</description>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_label>Dose 2</arm_group_label>
    <arm_group_label>Dose 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Japanese male or female patients, aged 40 years or older, with knee osteoarthritis

          -  Diagnosis of primary knee osteoarthritis, based upon the following:

               -  X-ray or magnetic response imaging (MRI) evidence within the last 6 months for
                  joint space narrowing and osteophyte formation

               -  Patients will be Kellegen and Lawrence classification II or III, and total
                  Western Ontario McMaster (WOMAC) score below or equal to 72

               -  Patients fulfilling the American College of Rheumatology Clinical and
                  Radiographic criteria for Osteoarthritis

        Exclusion criteria:

          -  Women of child bearing potential

          -  Secondary osteoarthritis: e.g., autoimmune disease, joint dysplasia, aseptic
             osteonecrosis, acromegaly, Paget's disease, Ehlers-Danlos syndrome, Gaucher's disease,
             Stickler's syndrome, joint infection, hemophilia, hemochromatosis, calcium
             pyrophosphate disposition disease, or neuropathic arthropathy

          -  Presence of local skin abnormality at the affected knee joint

          -  Any patient who received intra-articular injection within 3 months prior to
             administration

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 392001</name>
      <address>
        <city>Osaka-Shi</city>
        <zip>532-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2012</study_first_submitted>
  <study_first_submitted_qc>January 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2012</study_first_posted>
  <last_update_submitted>September 28, 2012</last_update_submitted>
  <last_update_submitted_qc>September 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

